Hogan Lovells strengthens pharmaceutical and biotechnology team with former FDA Chief of Staff Elizabeth Jungman

Jungman brings deep FDA experience through her leadership across multiple branches of government. As Chief of Staff, she oversaw the day-to-day management of the agency and provided strategic counsel to agency leadership. At CDER, Elizabeth advised senior agency officials on drug policy development, implementation, and long-range strategic goals—helping to oversee regulations and procedures impacting nearly every aspect of CDER. She has also held senior roles at The Pew Charitable Trusts and the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP), where she was a key drafter and negotiator of the FDA Safety and Innovation Act of 2012, among other landmark legislation.

"We are excited to welcome Elizabeth to the firm," said Janice Hogan, Practice Group Leader of the firm's Global Regulatory & IP Practice Group. "Her unparalleled experience at the FDA and on Capitol Hill positions her to offer strategic guidance to clients navigating a rapidly changing regulatory and policy landscape. She brings exceptional insight and judgment to our Pharmaceuticals and Biotechnology practice."

"Bringing on Elizabeth further strengthens our capabilities to provide strategic counsel on the most complex challenges facing pharmaceutical and biotech companies today," Lynn Mehler, Head of the firm's Pharmaceuticals and Biotechnology practice, said. "Elizabeth has long been recognized as a go-to policy guru within the pharmaceutical regulatory space, with deep experience in the cutting edge regulatory issues that are top-of-mind for many of our clients. She will be an invaluable asset across the practice."

Jungman is a nationally recognized thought leader in drug regulatory policy, with more than two decades of experience at the intersection of law, regulation, and public health. She has built a career focused on the development, interpretation, and application of pharmaceutical laws and regulations—making her uniquely qualified to help clients address high-stakes regulatory issues and complex policy challenges.

"I'm thrilled to be joining Hogan Lovells and to work alongside such a talented and collaborative team,” said Jungman. “The firm's global platform and deep regulatory bench make it an ideal home to help clients navigate the complex and evolving pharmaceutical policy environment. I look forward to helping clients solve some of the most pressing challenges in the industry."

Ajay Kuntamukkala, Office Managing Partner of the Washington, D.C. office, noted: "Elizabeth's arrival reflects our continued investment in top-tier legal talent across our regulatory teams. Her leadership at the highest levels of government, including her experience advising on major FDA policy initiatives and regulatory reform, will bring unmatched value to our clients."

Elizabeth's addition comes at a time of continued growth for Hogan Lovells' Global Regulatory practice and underscores the firm's commitment to expanding its capabilities in high-stakes policy advisory work across the life sciences sector.

About the Hogan Lovells Washington, D.C. office

Since 1904, our lawyers in the nation's capital have been instrumental in assisting clients in resolving their most difficult commercial, regulatory, and legal obstacles. Hogan Lovells' Washington, D.C. office is the firm's largest office in the United States, with over 500 lawyers spanning all three of the firm's practice groups -- Corporate & Finance, Global Regulatory and IP, and Litigation, Arbitration and Employment. We operate at the intersection of business and government, with a deep understanding of how geopolitics, political risks, and regulatory issues affect clients across numerous sectors.